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1 Introduction
Premature rupture of the fetal membranes
(PROM) leads to two main perinatal problems:
prematurity and infection [3]. Prematurity occurs
because usually labor begins shortly after the
rupture [8]. Infection is the consequence of an
open amniotic fluid cavity allowing germs to
contaminate both the mother and the fetus [20].
In the literature, there is a lack of consensus
about the attitude to adopt towards premature
rupture of membranes [7J. The obstetrician is
confronted with the choice of an optimal follow-
up either with or without tocolysis [19, 22], an-
tibiotic prevention [20] and hyaline membrane
disease prevention by glucocorticoids [3, 4], de-
pending on the risk for the neonate and the
mother.
In the "Cliniques Universitaires St Luc Brussels"
an active conservative management is the option
taken. After ten years of practice, we have eval-
uated our results by analyzing the perinatal out-
come and also by comparing the premature neo-
nates after PROM with a control group.
2 Methodology
Two hundred and fifteen women between 24 and
36 weeks of pregnancy with premature rupture
of the membranes (PROM) were admitted in this
study.
Diagnosis of PROM was based on patient's story,
sterile speculum examination showing pooling
amniotic fluid, and microscopic examination for
"ferning". At admission, a cervical culture for
group β streptococcus was performed. An ultra-
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sound examination and an electronic heart rate
fetal monitoring was utilized to assess fetal well
being.
Criteria of exclusion were: major fetal congenital
anomalies, fetal death, fetal distress, multiple
pregnancies, women in labor and any obstetrical
reason for immediate delivery such as vaginal
bleeding or evidence of chorioamnionitis.
Treatment consisted in bed rest at the hospital,
antibiotics continuously given (ampicillin 3 χ l g
IVD or erythromicin 4 χ 500 mg in case of al-
lergy), and intravenous tocolysis by ritodrine if
labor began. No vaginal desinfection was per-
formed.
Glucocorticoids ( -methasone 12 mg/day IM for
two days repeated once a week) were given only
before 32 weeks and by the discretion of the
attendant physician.
Follow-up of the patients consisted of measuring
the maternal temperature, evaluating uterine
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tenderness, and performing fetal heart rate mon-
itoring twice a day. Maternal leucocytosis and
blood sedimentation speed was measured every
two days. Once a week an ultrasound examina-
tion was performed to check fetal well being. A
cervical/vaginal culture was also done once a
week to certify a local sterilization. In case of
resistance to ampicillin, the antibiotic treatment
was adapted.
Pregnancy was terminated in case of suspected
chorioamnionitis (based on any of the following
signs: maternal fever greater than 38 °C; leuco-
cytosis superior to 15000; uterine tenderness; foul
smelling amniotic fluid discharge), fetal distress,
labor despite tocolysis, and when gestational age
reached 37 weeks. Antibiotics were given during
seven days after birth to all patients. The latency
period is the time between membrane rupture
and birth. A latency period of less than two days
is considered a failure of conservative manage-
ment.
Results were evaluated by the neonatal outcome:
prematurity, birth weight, Apgar score at 1 and
5 min, incidence of neonatal hyaline membrane
disease (HMD), neonatal infection, and early
neonatal death (first week of life). Diagnosis of
hyaline membrane disease was based on clinical
evaluation and on characteristic lung radiogra-
phy; wet lung, transcient respiratory distress, and
post-anoxic distress were diagnosed seperate
from HMD.
Neonatal infection consisted of a positive central
culture such as blood, cephalo-rachidian fluid or
urine, or a clinical evaluation showing evidence
of infection (leucocytosis, response to anti-
biotics, ...).
Neonatal outcome was compared to neonatal
outcome of babies born prematurely for another
etiological reason; each premature neonate fol-
lowing PROM was matched with a premature
neonate of the same birth age and year of birth
in order to compare similar neonatal manage-
ment. The benefit of pregnancy prolongation
after PROM and the group of neonates born at
37 weeks of gestation (not premature) were not
considered when compared to the control group.
Statistical analysis consisted of Chi-square tests
of independence performed on groups separated
by the procedure CROSSTAB of the statistical
package SPSS [26].
3 Results
From 1978 to 1987, 215 women with single preg-
nancies and PROM entered this retrospective
study. Gestational age ranged from 26 weeks to
36 weeks of amenorrhea, 113 PROM cases oc-
cured before 35 weeks.
Reasons for termination of pregnancy and the
overall neonatal results are listed (table I). In
our series we had no congenital malformation
and no prenatal death.
Pregnancy age at membrane rupture is a major
factor in determining the outcome (table II). The
latency period decreases with advanced gesta-
tional age. Suspicion of chorioamnionitis is sig-
nificantly more frequent at low gestational age.
The overall neonatal outcome is highly signifi-
cantly (P < 0.01) related to gestational age. In
the group of PROM occuring at 35 and 36 weeks
of gestation, there is no neonatal death, no
HMD, and only one case (1 %) of neonatal in-
fection.
Glucocorticoid treatment in PROM occuring be-
fore 33 weeks of pregnancy was administrated
in 28 cases out of 58 (48.3%). No difference in
neonatal outcome are found respectively with
and without treatment: rates of hyaline mem-
brane disease (17.9% vs 20.0%), of neonatal
infection (21.4% vs 26.7%) and of neonatal
death (10.7% vs 3.3%) are similar. The rate of
suspected chorioamnionitis is also similar in the
two groups (35.7% vs 36.7%).
When pregnancy is terminated because of the
suspicion of chorioamnionitis, the neonatal out-
come is compromised; the incidence of neonatal
infection is significantly (P < 0.001) related to
the suspicion of chorioamnionitis (table III). Sev-
enty cases (32.6%) of PROM had a prolonged
latency period (> 7 days). When comparing the
pregnancy outcome with PROM having a
shorter latency period, we found no difference.
Especially, the incidence of chorioamnionitis
(14.5% vs 24.3%, respectively in the short and
prolonged latency groups) and of neonatal in-
fection (6.9% vs 12.9%) are not statistically dif-
ferent.
When pregnancy termination was motivated by
a gestational age of 37 weeks, (N = 46, 21.4%)
fetal grwoth seems to be slowed down. Indeed,
the incidence of birth weight inferior to the tenth
percentile was significantly (P < 0.001) more fre-
quent in the group reaching 37 weeks of gestation
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Table I. Premature rupture of the membranes:
Termination of pregnancy:
— suspicion of chorioamnionitis
— 37 weeks reached
— failure of tocolysis




* before 37 weeks
* before 35 weeks
* before 33 weeks
— birth weight:
* < 1000 g
* < 1500 g
* <2000g
* <2500g
— Apgar scores < 7:
* at 1 min
* at 5 min

















































































(N = 9,19.6%; versus N = 4, 2.4% in the group
not reaching 37 weeks).
When PROM led to premature birth, the pre-
mature neonates before 33 weeks of gestation
did not differ from the control premature neo-
nates (table IV). When birth happened before 35
weeks and before 37 weeks, there is a lower
incidence of HMD and neonatal death in pre-
mature neonates following PROM compared to
the control group.
4 Discussion
The first problem relating to PROM seems to be
infection, maternal and/or neonatal. The studies
of JOHNSON [18], MILLER [20] and BLACKMON [3]
show that the later the PROM occurs during the
pregnancy, the smaller is the overall risk of in-
fection. This is in agreement with our results.
However, according to others, pregnancy age
modifies the risk of chorioamnionitis but not the
neonatal sepsis [1].
The controversy about the benefit versus the risk
of delaying labor after PROM is the main prob-
lem concerning the management of PROM. Ac-
cording to the literature, the risk of chorioam-
nionitis is variously related to the latency period:
many authors find no relationship [6, 14, 18, 20,
28, 36, 38] while others find a negative relation-
ship [1, 9, 12, 16,33,34].
Similar controversial results are found about the
incidence of neonatal infection, but the actual
conclusion seems to be that there is no relation-
ship between the length of the latency period and
the neonatal infection [1, 3, 9, 16, 28, 30]. We
find that a prolonged latency period (> 7 days)
does not increase the risk of chorioamnionitis
nor the risk of neonatal infection.
The benefit of conservative management lies in
the reduction of HMD, a major complication of
prematurity. A recent report [3] shows the posi-
tive effect of a prolonged latency even if previous
studies tend to find no relationship [1, 9, 11, 19,
23, 34]. Our results however, also show a trend
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Table HI. Effect of chorioamnionitis on neonatal outcome
Chorioamnionitis
N = 38 7.7%
No chorioamnionitis
N = 177 82.3%
CHi2
Prematurity:
* before 37 weeks
* before 35 weeks
* before 33 weeks
Birth weight:
* < 1000 g
* < 1500 g
* < 2000 g
* <2500g
Apgar scores < 7:
* at 1 min
































































of decreasing incidence of HMD with prolonged
latency, but it is not statistically significant
(P = 0.079 for PROM before 35 weeks).
In order to accelerate lung maturation, the
administration of ß-methasone is recommended
[29]. The majority of reported studies find no
difference in the incidence of HMD when corti-
costeroids were given [3, 4, 13, 19, 38]. Our
results are in agreement with these studies. But,
according to SPINNATO [32] these results are not
to be considered because the treatment is applied
to a low risk population and needs, for further
evaluation, to be applied where the potential
benefit of lung maturation really exists. Corti-
coids are known to be related to an increased
risk of infection, and in a situation such as
PROM where infection is threatening it may be
dangerous to use them. For some authors glu-
cocorticoid administration increases the mater-
nal infection risk but not the neonatal infection
risk [1], while for other authors it increases the
neonatal but not the maternal infection risk [31].
Other authors find that glucocorticoid adminis-
tration does not increase any infection risk [38],
and finally, there are authors who find an in-
creased maternal and neonatal infection risk [3,
24]. We do not find any increased incidence of
chorioamnionitis nor neonatal infection when
patients received ß-methasone. Since we observe
no benefit in glucocorticoids administration and
there is doubt about the infection risk, we rec-
ommend to not use them.
When chorioamnionitis is clinically suspected,
pregnancy should be stopped. The increased risk
of neonatal infection associated with chorioam-
nionitis seems generaly accepted [2, 3, 20] but
the relation with neonatal death is still contro-
versial [16, 34, 40]. Our results show that clinical
suspicion of chorioamnionitis is related with a
higher incidence of neonatal infection but not
with higher neonatal death rate.
Hypoplastic lungs after prolonged PROM is well
described [26, 37]. For some authors, PROM
does not affect the growth process [3,18] but for
others, PROM slows the growth [5, 35]. In our
study we have no prenatal death, no congenital
malformation, but fetuses seem to be slower in
their growth. Our control group compares the
premature neonate after PROM with a control
premature neonate. The results show less HMD
and a lower rate of neonatal death after PROM.
The principle that PROM decreases the risk of
HMD [3, 9] and the results of BLACKMON [3]
who finds a decreased perinatal mortality are in
agreement with our results. MOBERG [21] finds
an increased incidence of neonatal infection fol-
J. Perinat. Med. 17 (1989)
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lowing PROM, which contradicts the findings of
CURET [9]. When we compare premature neo-
nates after PROM to the control premature neo-
nates, there is no difference in the infection risk.
Our management of PROM which consists of
an active and conservative management differs
from the actual approach recommended by the
literature [1, 4, 8, 12, 16, 19, 22, 24, 28]. Never-
theless, we think that our management is justi-
fiable. PROM occuring before 28 weeks of ges-
tation generally leads to fetal loss. However, our
management led to a neonatal mortality rate of
only 12% with a rate of 29% for HMD, 25%
of neonatal infection and 33% of birth weight
under 1000 g. We had no latency period of less
than two days. Moreover, when PROM occured
after 34 weeks of pregnancy, our conservative
management avoided prematurity in 38% of the
neonates with no neonatal death and no HMD.
Only one case (1%) of neonatal infection was
the resulting risk.
When compared with the literature, our rate of
chorioamnionitis seems rather high: 18% before
37 weeks versus 12% [11], 5.2% [38], 5.3% [6]
and 27% before 35 weeks versus 16% [15], 27%
[27], 18% [17], 25% [16]. However, when com-
paring the neonatal outcome, which is the most
important criteria, our PROM management is
substantially more encouraging than the tradi-
tional management (table V).
Abstract
The aim of the study is to evaluate an active conserv-
ative management (tocolysis and antibiotics adminis-
tration) in preterm premature rupture of the mem-
branes (PROM), applied to 215 singleton pregnancies.
Pregnancies are continuated until 37 weeks of gestation
if the clinical and biological follow-up shows no risk
for the mother and the fetus. The neonatal results were
analysed by statistical methods and were compared to
the outcome of a control group of premature neonates.
Our results show that the outcome is mostly deter-
mined by gestational age at membrane rupture. No
benefit nor risk was added when glucocorticoids were
administrated. Clinical suspicion of chorioamnionitis
increases the risk of neonatal infection. A prolonged
latency period (> 7 days) does not increase the mater-
nal or fetal infection risk. When birth happened before
35 weeks and before 37 weeks, the premature neonate
after PROM has a lower incidence of hyaline mem-
brane disease and neonatal death compared with the
control group. These results are in favor of an active
conservative management in PROM.
Keywords: Chorioamnionitis, glucocorticoid, hyaline membrane disease, latency period, neonatal death, neo-
natal infection, premature rupture of fetal membranes.
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Zusammenfassung
Neonatales Outcome in 215 Fällen bei vorzeitigem Bla-
sensprung und aktivem „klassischen" Management
Der vorzeitige Blasensprung bei Geburtsunreife ist ein
Hauptproblem der Geburtshilfe. In unserer Abteilung
führen wir eine Antibiose sowie eine Tokolyse mit
Ritodrin durch. Wenn aus geburtshilflicher Sicht Glu-
kokortikoide gerechtfertigt erscheinen, werden diese
zur Akzeleration der Lungenreifung eingesetzt. Wir
würden dieses Vorgehen als aktives konservatives bzw.
klassisches Management bezeichnen. Der klinische
Verlauf sowie die Kontrolle der Laborparameter erlau-
ben die Fortsetzung der Schwangerschaft ohne Risiko,
welches meist durch eine Infektion droht, für Mutter
und Fet. Mit Erreichen der 37. Woche wurden die
Schwangerschaften beendet. Über einen Zeitraum von
10 Jahren wurde dieses Vorgehen bei 215 Einlings-
schwangerschaften mit vorzeitigem Blasensprung und
Geburtsunreife angewandt. Das neonatale Outcome
wurde statistisch analysiert. Darüberhinaus haben wir
dieses Kollektiv verglichen mit einer Kontrollgruppe
von Frühgeborenen ohne vorzeitigen Blasensprung.
Die Ergebnisse zeigen, das das Outcome in erster Linie
durch das Gestationsalter zum Zeitpujkt des Blasen-
sprung bedingt ist (Tabelle II). Die Gabe von Gluko-
kortikoiden brachte keine Vorteile, erhöhte aber auch
nicht das Risiko. Bei klinischem Verdacht auf eine
Chorioamnionitis wurde häufiger eine neonatale In-
fektion bestätigt (Tabelle III). Eine längere Latenzzeit
(> 7 Tage) erhöhte nicht das Risiko einer maternalen
oder fetalen Infektion. Bei Geburt vor der 35. bzw.
vor der 37. Woche hatten Frühgeborene nach vorzei-
tigem Blasensprung seltener ein Atemnotsyndrom als
Kinder der Kontrollgruppe. Auch die neonatale Sterb-
lichkeit war geringer (Tabelle IV).
Diese Ergebnisse haben ihren Stellenwert in den zahl-
reichen und kontroversen Arbeiten zum vorzeitigen
Blasensprung. Unser aktives „klassisches" Manage-
ment stimmt nicht mit der heutigen Vorgehensweise
beim vorzeitigen Blasensprung überein. Dennoch sind
unsere Ergebnisse hinsichtlich des neonatalen Outcome
im Literaturvergleich ermutigend (Tabelle V).
Schlüsselwörter: Atemnotsyndrom, Chorioamnionitis, Glukokortikoide, Latenzzeit, neonatale Infektion, neo-
natale Sterblichkeit, vorzeitiger Blasensprung.
Resume
Rupture prematuree des membranes ovulaires: resultat
neonatal dans 215 cas d'un traitement conservateur actif
La rupture prematuree des membranes ovulaires
(RPM) est un probleme obstetrical majeur qui bene-
ficie dans notre institution d'un traitement conserva-
teur actif. Le traitement consiste en une antibiotherapie
et en une tocolyse ä base de ritodrine ainsi que Pad-
ministration de glucocortico'ides dans le but d'accelerer
la maturation pulmonaire, si Petat obstetrical en in-
dique Putilite. Une surveillance clinique et biologique
pennet de prolonger la grossesse sans risques (princi-
palement infectieux) pour la mere et le fetus. Une fois
le terme de 37 semaines atteint, la grossesse est inter-
rompue. Sur une periode de 10 ans ce traitement a ete
applique ä 215 grossesses monofcetales avec RPM. Les
resultats perinataux ont ete evalues par analyse statis-
tique. Nous avons egalement compare le devenir neo-
natal des nouveaux-nes prematures apres RPM ä un
groupe contröle de prematures.
Le resultat neonatal semble principalement determine
par Tage gestationnel au moment de la rupture (tableau
II). Aucun benefice ni risque n'ont ete mis en evidence
suite ä Padministration de glucocorticoi'des. La suspi-
cion clinique de chorioamniotite augmente le risque
d'infection neonatale (tableau III). Une periode de
latence prolongee (> 7 jours) n'augmente pas le risque
infectieux maternel ou neonatal. Quand la naissance
survient avant 35 semaines et avant 37 semaines, la
prematurite apres RPM presente un taux de maladie
des membranes hyalines et de mortalite neonatale plus
bas que celui du groupe contröle (tableau IV).
Ces resultats s'inscrivent dans Pabondante et contra-
dictoire litterature concernant la RPM. Notre traite-
ment conservateur actif ne correspond pas ä Papproche
actuelle de la RPM, mais nos resultats neonataux
compares a ceux de la litterature sont encourageants
(tableau V).
Mots-cles: Choriamniotite, deces neonatal, glucocortico'ides, infection neonatale, maladie des membranes
hyalines, periode de latence, rupture prematuree des membranes ovulaires.
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